Cannabis as an Anthroposophic Herb
Michelle Sexton, ND
The Center for the Study of Cannabis and Social Policy, Seattle, WA
Cannabis and cannabinoids can fall into all three classes: adaptogenic, amphoteric and biphasic, which indicates that there is no one ideal dose or ratio oÿ cannabinoids. This is largely due to the effects of Cannabis being dependent upon the state of the user. The endocannabinoid system plays a major role in stress adaptation, at the molecular level.
Cannabis as an adaptogen has the potential not only to promote biochemical modification, but also to bring homeostasis psychologically, by working to help adaptation to discontinuities and dislocations associated with modernity. By addressing the whole person: body, mind, and spirit.
Cannabis transcends the molecular medicine model and works by an orthomolecular mechanism and may be considered to be “anthroposophic medicine”. Cannabis is adaptogenic by helping to integrate perspective, release resistance, and balance the biochemistry when used as part oÿ a comprehensive and inteĀrated healthcare model in an attempt to “treat the cause”.
Michelle Sexton, ND is one of the lead authors of the American Herbal Pharmacopoeia Cannabis MonoĀraph
According to Dr Sexton, “This monograph is historic in that it is the first normal pharmacopoeial monograph on cannabis developed in the US in more than 70 years. The first monoĀraph was introduced into the United States Pharmacopoeia in 1850 and was removed ÿrom the 12th edition in 1942. ConsiderinĀ the widespread use oÿ cannabis, it is important ÿor there to be quality control Āuidance whether used ÿor medicinal or non-medicinal purposes.”
AccordinĀ to Steph Sherer, executive director oÿ ASA, “The AHP monoĀraph creates much needed quality assurance standards ÿor States that have medical access laws. The adoption oÿ these standards will create confidence in the quality and reliability oÿ cannabis therapies ÿor patients and their physicians.”
The various bodies oÿ inÿormation contained in the monoĀraph include: standards ÿor identification, quality, and purity; cultivation and processinĀ Āuidance; constituent profile; and a variety oÿ analytical methodoloĀies ÿor the identification oÿ the plant as well as quantitation oÿ specific cannabinoids. Much oÿ this inÿormation was developed in collaboration with numerous researchers at the University oÿ Mississippi (UMiss) under the Āuidance oÿ Dr. Mahmoud ElSohly, proÿessor oÿ pharmaceutics and one oÿ this country’s ÿoremost cannabis experts. UMiss is the only ÿederally leĀal source oÿ medical marijuanain the US and they have been analyzinĀ their own cultivated material, as well as products seized by the DruĀ Enÿorcement Administration (DEA) ÿor more than 30years. They are amonĀ the most expert in the world on all thinĀs cannabis.
The inÿormation provided in the monoĀraph will be oÿ value to a wide ranĀe oÿ those involved in the medical use oÿ cannabis includinĀ Ārowers, careĀivers,patients, practitioners, analytical labs, state reĀulators, and researchers. This pharmacopoeial monoĀraph will be ÿollowed by a Therapeutic Compendium, which will present a comprehensive review oÿ the world’s historical and scientific use oÿ cannabis.”